A Phase II Study of Perioperative Paclitaxel in Patients With Gastric Adenocarcinoma and Carcinomatosis or Positive Cytology

This study is testing whether adding paclitaxel (a chemotherapy drug) delivered directly into the abdomen (intraperitoneally) alongside intravenous chemotherapy helps patients with stomach or gastroesophageal junction cancer that has spread to the lining of the abdominal cavity (peritoneal carcinomatosis) or has abnormal cancer cells in the abdominal fluid. **You may be eligible if...** - You are 18 or older - You have adenocarcinoma of the stomach or gastroesophageal junction confirmed by biopsy - Cancer cells have been found in your abdominal fluid or on the peritoneum (abdominal lining) - You have completed pre-operative chemotherapy - Your blood counts, kidney, and liver function are adequate - You are in reasonably good health (ECOG performance status 0–2) **You may NOT be eligible if...** - Your cancer cannot be detected in the abdomen - You are under 18 years old Talk to your doctor to see if this trial is right for you.